✦ LIBER ✦

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

✍ Scribed by Razis, Evangelia; Pentheroudakis, George; Rigakos, George; Bobos, Mattheos; Kouvatseas, George; Tzaida, Olympia; Makatsoris, Thomas; Papakostas, Pavlos; Bai, Maria; Goussia, Anna; Samantas, Epaminontas; Papamichael, Demetrios; Romanidou, Ourania; Efstratiou, Ioannis; Tsolaki, Eleftheria; Psyrri, Amanda; De Roock, Wendy; Bafaloukos, Dimitrios; Klouvas, George; Tejpar, Sabine; Kalogeras, Konstantine T.; Pectasides, Dimitrios; Fountzilas, George

Book ID: 125347611
Publisher: Springer-Verlag
Year: 2014
Tongue: English
Weight: 596 KB
Volume: 140
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-014-1626-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tumour gene expression predicts response

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

✍ Baker, J B; Dutta, D; Watson, D; Maddala, T; Munneke, B M; Shak, S; Rowinsky, E 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 640 KB

MicroRNA profiling predicts survival in

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF

✍ Neda Mosakhani; Leo Lahti; Ioana Borze; Marja-Liisa Karjalainen-Lindsberg; Jari 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 192 KB

Epidermal growth factor receptor R521K p

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy

✍ Yao-Yu Hsieh; Cheng-Hwai Tzeng; Ming-Huang Chen; Po-Min Chen; Wei-Shu Wang 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB

Quality of life analysis in patients wit

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin

✍ Láng, István; Köhne, Claus-Henning; Folprecht, Gunnar; Rougier, Philippe; Curran 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Analysis of PTEN, BRAF and PI3K status f

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

✍ Tural, Deniz; Batur, Sebnem; Erdamar, Sibel; Akar, Emre; Kepil, Nuray; Mandel, N 📂 Article 📅 2013 🏛 S. Karger AG 🌐 English ⚖ 467 KB

Insulin-like growth factor 1 expression

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan

✍ Mario Scartozzi; Alessandra Mandolesi; Riccardo Giampieri; Chiara Pierantoni; Fo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 245 KB

## Abstract Seventy to 40% of K‐RAS wild type colorectal tumors does not seem to benefit from treatment with antiepidermal growth factor receptor (anti‐EGFR) monoclonal antibodies. Recent data suggested that in presence of IGF‐1 system, altered activation colorectal cancer cells may escape anti‐EGF